We have recently entered into a collaborative research agreement with Molmir Corporation (hereinafter referred to as “Molmir”), a biotechnology venture dedicated to drug development for Amyotrophic Lateral Sclerosis (ALS). Molmir’s molecular dynamics assessment technology excels in in vitro evaluations, while Jiksak’s neural organoid technology demonstrates strength in assessments within neural tissues. By integrating the distinct technologies of both companies, we will accelerate the development of ALS therapeutic drugs.
Molmir Co., Ltd. announcement link